InSite Vision Appoints New Vice President of Operations

InSite Vision Incorporated (AMEX:ISV) today announced that Surendra Patel has joined the company in the newly-created position of Vice President, Operations. Mr. Patel will be responsible for the strategic direction and oversight of all operational activities for the company, including the expansion of commercial contract manufacturing for international sales of AzaSite®, InSite’s topical anti-infective ophthalmic product; the on-site production of clinical supplies for testing product candidates; and the planning and preparation of commercial capability for future products. "We welcome Surendra Patel at a time when we anticipate the need for expanding our operations to accommodate growing international sales of AzaSite and to prepare for our next product, ISV-502 (AzaSite Plus), currently in pivotal Phase 3 trials,” said S. Kumar Chandrasekaran, Chairman and Chief Executive Officer. "Surendra’s 30 years of experience with commercial manufacturing and drug development in the biopharma industry, combined with his management experience of both in-house operations and contract manufacturing, will contribute greatly to our ability to execute our strategy of growing the company to a multiple-product organization.” Mr. Patel has more than 30 years of development and operational experience in various management positions at pharmaceutical and biotechnology companies, including Syntex, Roche Bioscience, Oread Inc., DrugAbuse Sciences, and most recently, at Nektar Therapeutics where he served as Senior Director, Manufacturing Operations since 2002. While at Nektar he managed clinical and commercial manufacturing operations, plant maintenance, and calibration and warehouse operations that included the direction of more than 100 in-house personnel, and played a strategic role in the selection of domestic and international contract manufacturing sites. Experience at other companies includes the development of commercial and clinical manufacturing processes and sites; management of clinical trial material supply chains for development programs; selection and technical support for contract drug development and manufacturing; management of quality assurance compliance and quality assurance operations; manufacturing and packaging technology transfer between manufacturing plants; validation; and formulation and process development. Mr. Patel has a Bachelor of Science degree in pharmaceutical formulation from De Montford University, Leicester, United Kingdom. About InSite Vision InSite Vision develops novel topical anti-infective products, including AzaSite® (azithromycin ophthalmic solution) 1% which was launched in the United States by Inspire Pharmaceuticals for the topical treatment of bacterial conjunctivitis (pink eye). InSite has filed a New Drug Submission (NDS) with Health Canada seeking regulatory approval to market AzaSite in Canada. In addition, InSite signed licensing and distribution agreements with Shin Poong Pharm in South Korea; and with Bioceutica, Inc. for four countries in South America; and is seeking other international partners for commercialization and distribution of AzaSite. InSite is pursuing the expansion of its portfolio of anti-infective ophthalmic products to include ISV-502 (AzaSite Plus™) in Phase 3 pivotal trials as a product candidate directed at treating eye and eye lid infections, currently an unmet need particularly prevalent among the growing elderly population. In addition, InSite is evaluating the use of its product platform for ear infections with the product candidate, AzaSite Otic™ in preclinical development. The company is also developing AzaSite Xtra, an anti-infective eye product designed to assist in penetrating international markets. Additional information is available about the company at: http://www.insitevision.com. Forward Looking Statements This news release contains certain statements of a forward-looking nature relating to future events, such as the value brought to the company by Mr. Patel, and InSite’s plans for products outside of its AzaSite franchise, both within and outside of the ophthalmic market. Such statements entail a number of risks and uncertainties, including but not limited to: InSite’s reliance on third parties, including Inspire, for the commercialization of AzaSite and its other products; the ability of InSite Vision to enter into corporate collaborations for AzaSite outside the U.S. and Canada and with respect to its other product candidates, including ISV-502; Inspire’s ability to successfully market AzaSite in the United States and Canada; the clinical results of InSite’s product candidates; InSite Vision’s ability to expand its technology platform to include additional indications; InSite Vision’s ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite, AzaSite Plus, AzaSite Xtra and AzaSite Otic; and its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others; and determinations by the FDA, including those with respect to AzaSite Plus and AzaSite Otic. Reference is made to the discussion of these and other risk factors detailed in InSite Vision’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly reports on Form 10-Q, under the caption "Risk Factors” and elsewhere in such reports. Any forward looking statements or projections are based on the limited information currently available to InSite Vision, which is subject to change. Although any such forward looking statements or projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release is still valid at any later date.